Vemlidy tablets 25 mg for hepatitis B (Tenofovir)

What are Vemlidy tablets 25 mg for hepatitis B (tenofovir)?

Vemlidy tablets contain 25 mg of tenofovir, a nucleoside analogue reverse transcriptase inhibitor used for hepatitis B virus (HBV). It functions by inhibiting DNA polymerase, thereby blocking the replication of the hepatitis B virus. Vemlidy tablets are effective in reducing HBV levels within the body and preventing the infection of new liver cells. As a result, they can lower the risk of liver cancer, liver failure, and cirrhosis.

Clinical research indicates that during a 48-week treatment, 94% of patients who received tenofovir alafenamide had HBV DNA levels less than 29 IU/mL when using Vemlidy tablets. Furthermore, Vemlidy tablets demonstrated no signs of drug resistance in clinical trials. Due to its more efficient delivery to hepatocytes, individuals taking Vemlidy tablets experienced significantly lower bone mineral density when compared to those using tenofovir diproxil fumarate. As a result, Vemlidy tablets offer improved bone and renal safety.

Active principles: tenofovir alafenamide

Amount: 30 tablets

Maker: Gilead Sciences K. K., Tokyo, Japan

Indications: chronic hepatitis B virus infection

How to take

Adults should take 1 tablet (25 mg as tenofovir alafenamide) at a time, once a day. . Patients on dialysis must take the tablet immediately after dialysis.

The duration of the treatment is to be determined by your doctor, usually 6-12 months. 

Contraindications: do not use for pregnant or breastfeeding women. 

Important information

Patients should receive medical examination on a regular basis to avoid the mistaking symptoms of hepatic cirrhosis B for symptoms of chronic hepatitis B. 

Avoid taking any food or supplement containing St. John's wort while taking this medicine. 

If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.